Aerpio Pharmaceuticals Inc. (ARPO) and Moleculin Biotech Inc. (NASDAQ:MBRX) Comparing side by side

We will be comparing the differences between Aerpio Pharmaceuticals Inc. (NASDAQ:ARPO) and Moleculin Biotech Inc. (NASDAQ:MBRX) as far as profitability, institutional ownership, analyst recommendations, risk, dividends, earnings and valuation are concerned. The two businesses are rivals in the Biotechnology industry.

Valuation & Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Aerpio Pharmaceuticals Inc. 1 0.00 24.85M -0.36 0.00
Moleculin Biotech Inc. 1 0.00 34.23M -0.51 0.00

Table 1 shows gross revenue, earnings per share and valuation of the two companies.


Table 2 represents Aerpio Pharmaceuticals Inc. (NASDAQ:ARPO) and Moleculin Biotech Inc. (NASDAQ:MBRX)’s return on equity, net margins and return on assets.

Net Margins Return on Equity Return on Assets
Aerpio Pharmaceuticals Inc. 3,597,799,334.01% -20.5% -17.7%
Moleculin Biotech Inc. 2,986,129,285.53% -92.2% -65.2%


Aerpio Pharmaceuticals Inc.’s Current Ratio is 13.8 while its Quick Ratio is 13.8. On the competitive side is, Moleculin Biotech Inc. which has a 1.5 Current Ratio and a 1.5 Quick Ratio. Aerpio Pharmaceuticals Inc. is better positioned to pay off short and long-term obligations compared to Moleculin Biotech Inc.

Insider & Institutional Ownership

The shares of both Aerpio Pharmaceuticals Inc. and Moleculin Biotech Inc. are owned by institutional investors at 23.4% and 17.9% respectively. Aerpio Pharmaceuticals Inc.’s share owned by insiders are 1.1%. On the other hand, insiders owned about 23.73% of Moleculin Biotech Inc.’s shares.


In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Aerpio Pharmaceuticals Inc. 0.13% -8.73% -22.06% -79.51% -80.37% -53.24%
Moleculin Biotech Inc. -5.22% -12.1% -18.05% -20.44% -35.72% 4.81%

For the past year Aerpio Pharmaceuticals Inc. has -53.24% weaker performance while Moleculin Biotech Inc. has 4.81% stronger performance.


Aerpio Pharmaceuticals Inc. beats on 6 of the 9 factors Moleculin Biotech Inc.

Aerpio Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for ocular diseases. The company's lead product candidate is AKB-9778, a small molecule activator of the Tie2 pathway, which completed the Phase 2a clinical trial for the treatment of diabetic retinopathy. It also develops ARP-1536, a humanized monoclonal antibody that is in preclinical development stage for the treatment of diabetic vascular complications; and AKB-4924, a selective stabilizer of hypoxia-inducible factor-1 alpha, which has completed a single ascending dose clinical trial for the treatment of inflammatory bowel disease. The company is headquartered in Cincinnati, Ohio. Aerpio Pharmaceuticals, Inc.(OTCPK:ARPO) operates independently of Akebia Therapeutics, Inc. as of December 22, 2011.

Moleculin Biotech, Inc., a preclinical-stage pharmaceutical company, focuses on the development of anti-cancer drug candidates. Its lead drug candidate is liposomal Annamycin, an anthracycline intended for the treatment of relapsed or refractory acute myeloid leukemia. The company also develops other drugs, including WP1066 Portfolio that focuses on the modulation of regulatory transcription factors involved in the progression of cancer; and WP1122 Portfolio, a suite of molecules targeting the metabolic processes involved in cancer and glioblastoma. The company has an agreement with Mayo Clinic to enable additional research on its WP1066 molecule for the possible treatment of a rare form of pediatric brain tumor. It also has a strategic collaboration with the University of Bergen to develop immune stimulation drug, as well as to expand research on inhibition of brain metastasis by MoleculinÂ’s pre-clinical drug WP1066. Moleculin Biotech, Inc. was founded in 2015 and is headquartered in Houston, Texas.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.